KiraGen was selected as one of ten companies from more than 200 applicants for the Recode Edge '25 cohort, a pre-seed program for teams using artificial intelligence in healthcare.
The program included a Chicago bootcamp and company-building support from Recode Ventures, Eli Lilly and Company, Amazon Web Services, OpenAI, DLA Piper, and JPMorgan Chase. Cohort companies were eligible for up to $2 million in follow-on investment.
KiraGen used the cohort to support development of KiraLOGIC and its multiplex-engineered cell-therapy programs, beginning with glioblastoma. The team brought experience from Beam Therapeutics, bluebird bio, and Harvard.
